Related Experiment Video
Updated: Aug 26, 2025
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Safety of Remdesivir in 20 Children with COVID-19-Case Series-
Shuji Manabe1, Shinsuke Mizuno1, Tsuyoshi Jinda2
1Department of Infection, Kobe Children's Hospital.
Insights
Remdesivir (RDV) treatment for hospitalized children with COVID-19 showed positive outcomes. This study found RDV safe and effective in pediatric patients, with no serious adverse events reported.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Clinical Pharmacology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-COV-2, is a global health concern.
- Remdesivir (RDV) is an established treatment for severe COVID-19 in adults.
- Limited data exists on RDV's safety and efficacy in pediatric populations.
Purpose of the Study:
- To evaluate the safety and efficacy of remdesivir (RDV) in hospitalized children diagnosed with COVID-19.
- To assess adverse events and clinical outcomes in pediatric patients receiving RDV.
Main Methods:
- Retrospective study of 20 hospitalized pediatric patients with COVID-19 treated with RDV.
- Data collected from February to June 2022 at Kobe Children's Hospital, Japan.
- Analysis of patient demographics, underlying conditions, adverse events, and recovery.
Main Results:
- All 20 pediatric patients recovered without sequelae.
- No serious adverse events were reported during RDV treatment.
- Reported adverse events included elevated liver enzymes (20%), leukopenia (5%), neutropenia (5%), and hypokalemia (5%).
Conclusions:
- Remdesivir (RDV) appears to be safe and effective for treating COVID-19 in hospitalized children.
- The study suggests RDV can be a viable treatment option for pediatric COVID-19 cases.
- Further research is warranted to confirm these findings in larger pediatric cohorts.
Abstract:
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus, has spread worldwide since 2019. Several studies report that adult patients hospitalized with severe COVID-19 can be treated successfully with remdesivir (RDV). However, few studies report the safety and efficacy of RDV for children. This study included 20 hospitalized patients who were diagnosed with COVID-19 and received RDV at Kobe Children's Hospital, Japan, between February and June, 2022. The median age was 2 years (IQR, 1-11 years; range, 5 months to 19 years). Twelve (60%) patients were male. Three (15%) patients were previously healthy, whereas the other 17 had at least one underlying medical condition: five (25%) patients had respiratory disease, four (20%) had cardiac disease, three (15%) had central nervous system disease, four (20%) had hematologic or oncologic disease, and two (10%) had a chromosomal abnormal. All patients recovered without any sequelae, and no serious adverse events were reported. The adverse events were elevated liver enzymes in 4 children (20%), leukopenia (5%), neutropenia (5%), and hypokalemia (5%). Our study may show that the use of RDV for COVID-19 in children led to no serious adverse events.
Related Concept Videos
01:07Teratogenicity
01:21Factors Affecting Drug Response: Overview
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:12Relative Risk
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:29Subviral Agents